Press & Statements

CSRxP: USPTO WITHDRAWAL OF PATENT THICKET RULE ADDS TO URGENCY FOR CONGRESS TO PASS CORNYN-BLUMENTHAL

Dec 4, 2024

Lawmakers Must Act to Hold Big Pharma Accountable for Egregious Patent Abuse Read More

CSRxP STATEMENT ON SENATE JUDICIARY MARKUP OF THE PREVAIL ACT

Nov 21, 2024

Congress Should Not Further Consider Misguided Proposal That Would Enable More Read More

CSRxP ANALYSIS FINDS PHARMACEUTICAL INDUSTRY’S PROFIT MARGINS TEN TIMES GREATER THAN OTHER SECTORS OF DRUG SUPPLY CHAIN

Nov 20, 2024

Study Finds Big Pharma’s Price-Gouging and Patent Abuse Playbook Fuels Read More

CSRxP JOINS FELLOW ADVOCATES FOR LOWER DRUG PRICES TO URGE HOUSE JUDICIARY COMMITTEE TO CRACK DOWN ON BIG PHARMA’S PATENT ABUSE

Sep 6, 2024

Letter Encourages Lawmakers to Advance Bipartisan Solutions to Hold Big Pharma Read More

CSRxP APPLAUDS REINTRODUCTION OF REMEDY ACT IN U.S. SENATE 

Jul 31, 2024

Bipartisan, Market-Based Solution Would Help Crack Down on Anti-Competitive Read More

CSRXP: BIG PHARMA IS AT IT AGAIN, HIKES PRICES ON NEARLY 200 PRESCRIPTION DRUGS AS PART OF MID-YEAR INCREASES

Jul 15, 2024

Brand Name Drug Giants’ Average Price Increases for June-July Outpace Rate Read More